The defibrillator that saved Christian Eriksen’s life on the pitch is rapidly becoming the City’s latest export darling. British-made devices, built with the same meticulous precision as a gilt-edged bond, are now the gold standard in emergency cardiac care. The recent incident involving the Danish footballer has reignited debate about the cost of medical innovation versus the price of a life.
The NHS, already stretched by inflationary pressures, faces a stark choice: invest in world-class defibrillators or risk falling behind. Market efficiency suggests we cannot afford to hesitate. The bottom line: when seconds count, the price tag must not.
